Publications by authors named "A Fuerea"
Article Synopsis
- * KRAS mutations, which are common in CRC, have historically been difficult to target, but recent drug developments have introduced several KRAS inhibitors, including both covalent and non-covalent types.
- * Clinical trials are underway to test the effectiveness of these KRAS inhibitors, either alone or with other treatments, despite challenges like resistance and tumor diversity, indicating that these inhibitors could significantly enhance CRC patient outcomes in the future.
Pancreatic adenocarcinoma (PDAC) is a major health burden and may become the second cause of death by cancer in developed countries. The incidence of early-onset pancreatic cancer (EOPC, defined by an age at diagnosis <50 years old) is increasing. Here, we conducted a study of all PDAC patients followed at our institution.
View Article and Find Full Text PDFRole of molecular biology in the management of pancreatic cancer.
World J Gastrointest Oncol
July 2024
Pancreatic ductal adenocarcinoma (PDAC) presents significant challenges in patient management due to a dismal prognosis, increasing incidence, and limited treatment options. In this regard, precision medicine, which personalizes treatments based on tumour molecular characteristics, has gained great interest. However, its widespread implementation is not fully endorsed in current recommendations.
View Article and Find Full Text PDFBackground: Genomic studies have identified new subsets of aggressive prostate cancer (PCa) with poor prognosis (eg, neuroendocrine prostate cancer [NEPC], PCa with DNA damage response [DDR] alterations, or PCa resistant to androgen receptor pathway inhibitors [ARPIs]). Development of novel therapies relies on the availability of relevant preclinical models.
Objective: To develop new preclinical models (patient-derived xenograft [PDX], PDX-derived organoid [PDXO], and patient-derived organoid [PDO]) representative of the most aggressive variants of PCa and to develop a new drug evaluation strategy.